Therapeutic radiopharmaceuticals are a safe and effective targeted approach to treating many types of cancer. NorthStar is poised to be the first commercial-scale producer of the important therapeutic radioisotopes Ac-225 and Cu-67, both used to deliver precise therapeutic doses of radiation to destroy cancer cells in patients with serious disease while sparing healthy tissue.
HOW DOES RADIONUCLIDE
Radiopharmaceuticals suited for therapeutic purposes are those that strongly bind to the tumor.
They transport targeted doses of radiation directly to the tumor and its metastases, thereby sparing normal healthy tissue.
The carrier molecule type, such as antigens or receptors, is determined by its affinity to the tumor’s structure.
The ionizing radiation emitted by a radionuclide linked to the carrier, kills cancer cells by damaging their DNA, causing the tumors to shrink.